SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 16.59-2.7%Sep 20 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Fitzhughlaw9/12/2019 8:54:59 AM
15 Recommendations

Recommended By
bnutman
btlbail1
captcobra1
CelebrityEquity
corndog

and 10 more members

   of 52512
 
ESMO "Investor Event" presentation scheduled for this coming Saturday from Barcelona (12:30 p.m. EST), and some of the big hitters in oncology for this indication (Tagawa) and in an interesting but not to be overlooked development, breast cancer (Rugo), are participating:

Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. ( IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host an Investor Event on Saturday, September 28, 2019 at 6:30 p.m. Central European Summer Time in Barcelona, Spain, during the Congress 2019.

The event will feature presentations by key opinion leaders including Scott Tagawa, M.D., MS, Richard A. Stratton Associate Professor in Hematology & Oncology, Associate Professor of Medicine & Urology, Weill Cornell Medicine, and Associate Attending Physician, NewYork-Presbyterian – Weill Cornell Medical Center, who will present the interim results from TROPHY-U-01 at the Congress. Cora N. Sternberg, M.D., FACP, Clinical Director, Englander Institute for Precision Medicine and Professor of Medicine in Hematology & Oncology, Weill Cornell Medicine and NewYork-Presbyterian will discuss the implications of these data in an evolving metastatic urothelial cancer landscape.

In addition, Hope S. Rugo, M.D., FACP, Professor of Medicine; and Director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, will lead the discussion on the Company’s breast cancer programs. Members of Immunomedics leadership team will also be present to provide a corporate update.

For additional information and/or to RSVP for the event, please contact Dr. Chau Cheng at ccheng@immunomedics.com. The investor event will be webcast live via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a replay of the webcast will be available for approximately 30 days.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext